Global Integrated Partner Sygnature Discovery operates as a global drug discovery CRO with a large, diverse scientific workforce across Europe and North America, offering integrated services from target identification to candidate nomination. The track record of successful projects, numerous patents, and high customer retention highlight its ability to protect IP and deliver end-to-end discoveries for pharma and biotech clients.

Speed Through AI Recent investments in mammalian expression (ExpiCHO-S) and collaborations with Dalton TX, SygDesign, BullFrog AI, and Iktos position Sygnature as a speed-focused partner that blends wet-lab chemistry with AI-enabled design. A new head of in vivo pharmacology and a brand relaunch further signal expansion of capabilities and market readiness for fast, integrated programs.

Oncology ADC Leadership The company's core therapeutic focus includes oncology and immunology, with active participation in ADC discussions and partnerships; recent talks at World ADC London and collaborations with STORM Therapeutics to advance DHX9 inhibitor programs indicate a strategic emphasis on high-need areas and next-generation modalities.

Loyal Customer Base With a strong track record of customer retention and a broad portfolio of active projects, Sygnature offers multiple cross-sell opportunities across its protein science, chemistry, computational chemistry, in vitro biology, pharmacology, DMPK, formulation, and project management capabilities to existing clients.

Capacity and Efficiency Recent workforce reductions alongside investments in new platforms and partnerships indicate a focus on efficiency while continuing growth initiatives; clients should discuss capacity, lead times and flexible resourcing to ensure alignment with program timelines, supported by a global footprint.